CCT-217 represents a paradigm shift in obesity treatment through its revolutionary approach. "CCT-217's unique dual-mechanism approach represents a fundamental advancement in obesity treatment ...

Eli Lilly, a leading US pharmaceutical company, is gearing up to launch its groundbreaking diabetes and obesity medication, Tirzepatide—commercially known as Mounjaro—in India by 2025.

CCT-217 represents a paradigm shift in obesity treatment through its revolutionary approach. Breakthrough Preclinical Results: 26-34% total weight loss achieved through selective fat mass ...

Novel siRNA Therapeutic Demonstrates Significant Fat Loss and Remarkable Lean Body Mass Preservation, and Promises Superior Adherence Recent studies have highlighted significant challenges with ...

10, 2025 /CNW/ - Canary Cure Therapeutics, a pioneer in next-generation RNA therapeutics development, today announced breakthrough preclinical results for its lead candidate CCT-217, addressing two ...

10, 2025 /PRNewswire/ - Canary Cure Therapeutics, a pioneer in next-generation RNA therapeutics development, today announced breakthrough preclinical results for its lead candidate CCT-217, addressing ...